Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?
The best therapy regimen for refractory obstetrical antiphospholipid syndrome remains to be determined. Additional treatments with steroids, plasma exchanges and immunoglobulins failed to show any beneficial effect. We present a case of a woman who had a better pregnancy outcome after the administration of hydroxychloroquine (HCQ) as additional treatment. Furthermore, we highlighted that HCQ was able to dramatically reduce the antiphospholipid antibodies levels.
Department of Obstetrics and Gynecology, Catholic University of Rome, Italy.
S
S
De Carolis
Department of Obstetrics and Gynecology, Catholic University of Rome, Italy.
A
A
Botta
Department of Obstetrics and Gynecology, Catholic University of Rome, Italy.
S
S
Salvi
Department of Obstetrics and Gynecology, Catholic University of Rome, Italy. Electronic address: elviradp1@hotmail.it.
E
E
di Pasquo
Department of Obstetrics and Gynecology, Catholic University of Rome, Italy.
G
G
Del Sordo
Department of Obstetrics and Gynecology, Catholic University of Rome, Italy.
C
C
Garufi
Department of Obstetrics and Gynecology, Catholic University of Rome, Italy.
A
A
Lanzone
Department of Neonatology, Catholic University of Rome, Italy.
M P
MP
De Carolis
D000328:Adult; D017152:Antibodies, Antiphospholipid / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use*; D010641:Phenotype; D011247:Pregnancy; D011248:Pregnancy Complications; D011256:Pregnancy Outcome
D017152:Antibodies, Antiphospholipid; D006886:Hydroxychloroquine